Published in final edited form as:

Mol Pharm. 2010 February 1; 7(1): 245. doi:10.1021/mp900236t.

Inhibition of tumor metastasis: Functional immune modulation of the CUB Domain Containing Protein 1

Keisuke Fukuchi^{1,#,||}, Sebastian C.J. Steiniger^{1,#,⊥}, Elena Deryugina², Ying Liu¹, Colin A. Lowery¹, Christian Gloeckner¹, Bin Zhou¹, Gunnar F. Kaufmann¹, James P. Quigley², and Kim D. Janda^{1,3,*}

¹The Skaggs Institute for Chemical Biology and Departments of Chemistry, Immunology and Microbial Science, La Jolla, California, 92037

²Department of Cell Biology, The Scripps Research Institute, La Jolla, California, 92037

³Worm Institute of Research and Medicine (WIRM), La Jolla, California, 92037

Abstract

Despite significant progress and notable successes in tumor therapy, malignant disease remains an extremely difficult problem in today's health care setting. There is, however, an increasing application of new therapies targeting proteins specifically upregulated on tumor cells. These innovative therapeutic approaches are aimed at molecules that contribute to malignant development and progression but spare normal tissues. The CUB Domain Containing Protein 1 (CDCP1) is such a tumor-associated protein and thus, a potential candidate for targeted cancer immunotherapy. Herein, we describe the generation of function-blocking human antibodies against CDCP1 that were obtained from human scFv phage display libraries using subtractive panning protocols on CDCP1 expressing cancer cells and immunopurified CDCP1 protein. One of the isolated anti-CDCP1 antibodies, namely C20Fc, efficiently blocked experimental metastasis of human carcinoma cells, including HeLa cells stably transfected with CDCP1 and prostate carcinoma cells PC-hi/diss naturally expressing CDCP1, in both chick embryo and mouse model systems. The C20Fc antibody also reduced colony formation of CDCP1 expressing cells in a soft agar assay for anchorage-independent cell growth. Specific targeting of CDCP1 by C20Fc mediated the delivery of a toxin-conjugated antibody complex, thus, providing evidence for antibody internalization and specific killing of CDCP1-positive tumor cells. Our findings indicate a functional role for CDCP1 in human cancer and underscore the therapeutic potential of function-blocking anti-CDCP1 antibodies targeting both primary and metastatic carcinoma cells.

Keywords

Immunotherapy; CDCP-1; metastasis; human antibodies; carcinoma

Introduction

In 2001, the CUB Domain Containing Protein 1 (CDCP1) was identified as a human tumor-associated gene using representational difference analysis and cDNA chip technology.¹ Subsequently, CDCP1 protein levels were shown to be elevated in metastatic human tumor

kdjanda@scripps.edu.

[#]These authors contributed equally to this work

^{||}Current address: Daiichi Sankyo, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan

[⊥]Current address: XBiotech, 8201 E Riverside Drive, Austin, TX 78744.

cell lines and determined to be the target of the murine monoclonal antibody (mAb) 41-2.2 At present, the functional importance of CDCP1 has been reported in patients with metastatic gastric, lung and renal cell carcinomas as well as in a number of epithelial cancer cell lines.³⁻¹³ Importantly, CDCP1 has also been demonstrated to be expressed on cells phenotypically identical to hematopoietic stem/progenitor cells, mesenchymal stem/progenitor cells (MSCs) and neural progenitor cells (NPCs).^{14,15} However, the exact functional role of CDCP1 in cancer and stem cells is still poorly understood.

CDCP1 is a single pass transmembrane protein, containing three CUB domains with the extracellular portion most likely involved in cell-cell or cell-extracellular matrix interactions.¹⁶ It promotes invasion and peritoneal dissemination of cancer cells through the regulation of cell migration and anchorage independence.⁶ Notably, CDCP1 has been classified as a Src family kinase-binding phosphoprotein, both regulating cell adhesion and resistance to anoikis of cancer cells.²⁻⁴ However, tyrosine phosphorylation of CDCP1 has also been shown to be adhesion-dependent and regulated by protease cleavage in epithelial carcinomas.^{3,17} Furthermore, tyrosine phosphorylation is required for the binding of PKC δ to CDCP1.¹⁸

Several murine mAbs have been generated against CDCP1 by whole cell immunization, and have exhibited function-blocking activity in the chick embryo and mouse metastasis model systems.^{2,7,11} However, human mAbs specifically targeting CDCP1 expressed by human tumor cells have not been reported and if generated, such antibodies would have clinical relevance.

Materials and Methods

Cell lines and Culture Conditions

The human cervix adenocarcinoma epithelial cell line HeLa (ATCC CCL 2), human prostate carcinoma epithelial cell line PC-3 (ATCC CRL 1435) and African green monkey kidney fibroblast-like cell line COS-1 (ATCC CRL 1650) were purchased from American Type Culture Collection (ATCC, Manassas, VA). A high disseminating variant of the prostate carcinoma PC-3 cell line (PC-hi/diss) was generated by serial passaging of primary tumors developed in chick embryos as described.¹⁹ Tumor cells were cultured in DMEM supplemented with 10% fetal calf serum (D-10), 2 mM GlutaMax and antibiotics (Invitrogen, Carlsbad, CA).

Antibodies

Murine anti-CDCP1 mAb 41-2 was generated by subtractive immunization as described.² Murine anti-human transferrin receptor antibody was purchased from eBioscience (San Diego, CA). Normal mouse IgG was purchased from Jackson ImmunoResearch, Inc. (West Grove, PA). The control fully human antibody was an anti-anthrax spore fusion scFv-Fc antibody A4Fc made in our laboratory. Saporin-conjugated goat anti-mouse IgG (Mab-ZAP) and goat anti-human IgG (Hum-ZAP) secondary antibodies were purchased from Advanced Targeting Systems (San Diego, CA).

Generation of CDCP1 expressing HeLa cells

HeLa cells overexpressing CDCP1 protein (HeLa-CDCP1) were generated from parental carcinoma cells, previously demonstrated not to express any detectable CDCP1.² HeLa-CDCP1 cells were generated by stable transfection of CDCP1 cDNA in the pcDNA3.1-neo vector (Invitrogen) using Lipofectamine 2000 as described.¹¹ Several CDCP1-positive, drug resistant clones were combined to generate a HeLa-CDCP1 cell line. Control HeLa-neo cells were generated by transfection of parental cells with the empty vector. Expression of CDCP1

on the cell surface was confirmed using flow cytometry and western blot analysis with a mouse anti-CDCP1 mAb, 41-2.2.11

Combinational Panning

Phage library panning was conducted as previously described.^{20,21} In short, before each round of panning, the library was subtracted with CDCP1-negative HeLa-neo cells. A mixture of human scFv phage libraries (5×10^{12} cfu) was incubated with 5×10^7 HeLa-neo cells in 10 mL of culture medium for 1 h at 4 °C. In panning rounds 1–4 the subtracted scFv phage particles were added to HeLa-CDCP1 cells. The cells were incubated with the subtracted scFv phage library for 1 h at 4 °C, washed 5 times with 10 mL of ice-cold PBS, collected by a cell scraper and resuspended in 10 mL of ice-cold PBS. Alternatively, in the third and fourth round of panning; subtracted phages were panned on CDCP1 protein captured on STAR coated tubes (NUNC) for 1 hour at 4 °C. For CDCP1 capturing, the tubes were first incubated with mouse anti-CDCP1 mAb 41-2 at a concentration of 100 µg/mL in PBS for 2 h at room temperature, washed with PBS, and blocked with 2% casein-PBS. The cell lysate generated from approximately 3×10^7 HeLa-CDCP1 cells was added to mAb 41-2-coated tubes. Following incubation for 1 hour at 4 °C, the tubes were washed 3x with PBS and phage were added for 1 hour at 4 °C. Upon washing 3x with PBS, the bound scFv-phage were eluted with 1 mL elution buffer (100 mM HCl, adjusted to pH 2.2 with glycine) for 10 min at room temperature followed by neutralization with 50 µL of 2 M Tris-HCl, pH 8.9. The eluted phage were incubated with 10 mL of *E. coli* TG1 cells in exponential growth. The infected cells were collected by centrifugation (3000 rpm for 5 min), resuspended in 100 µL of Super broth (SB) broth medium, plated on 2% glucose, 100 µg/mL carbenicillin-containing Luria-Bertani (LB) broth agar plates, and incubated at 37 °C. After overnight incubation, the plates were scraped with 1 mL of SB medium supplemented with 15% glycerol, and 100 µL of the resulting suspension were inoculated into 20 mL of SB medium supplemented with 2% glucose, 20 mM MgCl₂, and 100 µg/mL carbenicillin. The culture was incubated at 37 °C, and the phagemid rescued by addition of 100 µL of VCSM13 helper phage (10^{11} pfu/mL; Stratagene), followed by incubation at 37 °C for 30 min without shaking and an additional 30 min incubation at the same temperature with agitation. The cells were then collected by centrifugation (3000 rpm for 15 min), resuspended in 100 mL of SB supplemented with 20 mM MgCl₂, 100 µg/mL carbenicillin, and 79 µg/mL kanamycin, and incubated at 28 °C overnight with shaking. The scFv-phage were purified by standard PEG precipitation.²²

Selection of positive antibody-phage clones by ELISA

HeLa-CDCP1 cells and HeLa-neo cells were incubated at 5×10^4 cells per 0.1 mL 10% fetal bovine serum (FBS) containing DMEM media in 96-well microtiter plates. After overnight incubation, 25 µL of scFv-phage solution were added to each well containing adherent HeLa cells and incubated for 1 hr at 4 °C. The plates were washed, 2x, with PBS containing 5% FBS, followed by incubation with HRP conjugated anti-M13 antibody (1:1000 in 5% FBS containing PBS) for 2 h at 4 °C. Following additional washes, the HRP substrate (TMB, Pierce) was added to the plates, the reaction was stopped by addition of 2M H₂SO₄ when an adequate signal was reached, and the absorbance was read at 450 nm.

Generation and purification of scFv-Fc fusion antibodies

The scFv gene fragments were subcloned into a pSec-Fc vector (derived from the original pSec vector, Invitrogen) containing the human antibody constant regions C_H2 and C_H3 derived from human IgG1 as well as *Sfi*I restriction sites to allow for subcloning of the scFv gene. The obtained plasmids were purified using EndFree plasmid Maxi Kit (Qiagen). The plasmid was transfected into 1×10^7 293 cells with Eugene 6 (Roche). Approximately 16 hours later, medium was exchanged for DMEM supplemented with 10 % ultra low IgG serum (Invitrogen) and 4

mM GlutaMax (Invitrogen). Transfected cells were incubated for 1 week at 37 °C in 5% CO₂, conditioned medium harvested and filtered through a 0.45 µm filter, and secreted human Fc-tagged scFv antibody (scFv-Fc fusion antibody) was purified using an HiTrap Mabselect Sure column (GE Healthcare, Piscataway, NJ) following the manufacturer's instructions.

Flow cytometry

Primary antibodies or purified scFv-Fc fusion antibodies were incubated with HeLa-CDCP1 and HeLa-neo cells (5×10^5 cells in 100 µL) on ice for 30 min. After washing with PBS, the cells were stained with FITC-conjugated goat anti-human IgG or anti-M13 phage antibody. Analysis of antibody binding was performed with a Becton Dickinson LSRII flow cytometric analyzer. The geometric mean of fluorescence intensity (geomean) was calculated using FlowJo software (TreeStar, Inc., Ashland, OR).

In vitro antibody internalization assay

The scFv-Fc antibodies or mouse monoclonal antibodies at 10 µg/mL were pre-incubated under shaking with the same concentration (1:1) of Hum-ZAP (Advanced Targeting Systems) or Mab-ZAP (Advanced Targeting Systems) in DMEM for 30 min at room temperature. These mixtures were used for in the cell proliferation assays. Thus, PC-hi/diss, HeLa-CDCP1 or HeLa-neo cells were plated in white 96-well microplate wells at 2,000 cells/45 µL. Next, a mixture of 400 ng of primary antibody with either 400 ng of the Mab-ZAP or Hum-ZAP secondary antibody with PBS as the vehicle instead of a secondary antibody, were added in a volume of 5 µL for a final volume of 50 µL. Ligation and internalization of the primary antibody resulted in delivery of the antibody conjugated saporin to the cell interior followed by cell killing. Plates were incubated for 48 h at 37 °C in the presence of 5% CO₂. Cell viability was assayed using a CellTiter GLO Cell Proliferation Assay according to the manufacturer's instructions (Promega), and the luminescence was determined in a Molecular Devices V_{max} microplate reader. Percent cell viability was calculated by assigning the average of the readings from secondary antibody goat IgG-SAP isotype controls with PBS as 100% cell viability. As a positive antibody control for internalization, the anti-transferrin receptor antibody OKT9 (eBioscience) was utilized.

Anchorage independence assay

Approximately 1 mL of complete DMEM containing 0.3% low melting point agarose (LMA) was added per well of a 6 well plate and placed at 4°C until the medium solidified. Plates were warmed at 37 °C, and then 1 mL of DMEM with 0.3% LMA, 200 µg of antibody and 1×10^4 cells were added to the solidified agarose layers. The plates were incubated for one hour at 4 °C and then transferred to a 37 °C incubator containing 5% CO₂. Every three days 0.5 mL of fresh medium containing 0.3% LMA was added to each well and let solidify for one hour at 4 °C. The cells were allowed to grow for 2 weeks in a cell culture incubator. The cell colonies were counted in 8 different areas of each well within the microscope field of view. The mean and S.D. were calculated per each condition and compared by Student's t-test for $P < 0.05$ to determine statistical significance between data sets.

Experimental Metastasis in Chick Embryos

Experimental metastasis was performed in chick embryos developing in fertilized SPAFAS White Leghorn eggs (Charles River). On day 12 of embryo development, 5×10^4 HeLa-CDCP1 or PC-hi/diss tumor cells were injected into the allantoic vein as described.¹¹ CDCP1 specific or control human antibodies were inoculated i.v. at 25 µg per embryo at the time of cell injections. Five days later, on day 17 of embryo development, portions of the CAM were harvested to determine numbers of human tumor cells that colonized the CAM tissue.

Experimental Metastasis in Mice

Female 6–8 week-old immunodeficient NOD-SCID mice (TSRI) were injected i.v. with 1×10^6 HeLa or 5×10^5 PC-hi/diss cells. At the time of cell injection, 100 μ g of human anti-CDCP1 or control antibodies were inoculated per animal. Additional antibody injections were performed i.p. on days 2 and 3 following cell inoculations. Four weeks (HeLa cells) or 8 weeks (PC-hi/diss) later, the mice were sacrificed and lungs were harvested to determine numbers of human tumors cells by quantitative Alu-PCR.

Quantitation of Human Tumor Cells by Real-Time Quantitative PCR (qPCR)

Numbers of human cells within murine or chick embryo tissues were determined by qPCR performed using a standard curve generated by serial dilutions of human tumor cells within a constant number (10^6) of chick embryo or mouse fibroblasts essentially as described.¹¹ Each assay included negative controls (i.e. water and tissue samples from the embryos that did not receive human cells), and experimental samples in duplicate.

Results

Panning of anti-CDCP1 single chain Fv antibodies

To generate anti-CDCP1 human single chain Fv antibodies (scFv) that recognize different epitopes on the CDCP1 molecule, two alternative panning strategies were utilized. The first approach employed phage panning on HeLa-CDCP1 cells that were stably transfected with a CDCP1 expression vector. After four rounds of panning, one scFv phage-displayed antibody was selected, namely C25, which demonstrated specific binding to HeLa-CDCP1 as determined by whole cell ELISA (Fig. 1). Alternatively, panning was performed on CDCP1 protein immuno-captured by anti-CDCP1 mouse mAb 41-2.² This panning approach resulted in the selection of antibodies C14 and C20 that specifically bound to HeLa-CDCP1 cells, but not to HeLa-neo cells (Fig. 1).

Sequence analysis for three positive clones demonstrated that each scFv was an independent clone expressing a unique amino acid sequence (Fig. 2). Alignment of the amino acid sequences of individual scFv showed that there was no significant sequence identity within the CDR regions of the heavy chain. However, the clones C14 and C25 had identical CDR L1 and L2 sequences and also exhibited strong similarity within CDR L3.

Generation of anti-CDCP1 scFv-Fc antibodies

In order to produce stable antibodies for *in vitro* and *in vivo* function blocking analyses, the human IgG Fc domain was appended to scFvs C25, C14 and C20 by subcloning the antibody genes into an expression vector containing the human Fc gene. The C-terminal Fc-fused antibodies (scFv-Fc) were expressed in 293 human kidney cancer cells and purified using a protein G column. The specificity of antibody binding was evaluated by flow cytometry with HeLa-CDCP1 and HeLa-Neo cells (Fig. 3). Fully human scFv-Fc fusion antibodies, i.e. C14Fc, C20Fc and C25Fc, demonstrated a specific high fluorescence signal with HeLa-CDCP1 cells and no signal with CDCP1-negative HeLa-neo cells.

Evaluation of anti-CDCP1 antibodies in an experimental metastasis model in chick embryos

To evaluate anti-metastasis activity of the anti-CDCP1 antibodies, a human tumor/chick embryo experimental model system was examined (reviewed in 11). This assay is based on inoculation of human cancer cells into the allantoic vein of the chick embryo and subsequent analysis of tumor cell colonization of the chorioallantoic membrane (CAM), serving as a lung analogue for the embryo. Thus, 5×10^4 HeLa-CDCP1 transfected cells, or PC-hi/diss cells naturally expressing CDCP1 were injected i.v. along with 25 μ g control A4Fc or individual anti-CDCP1

scFv-Fc. The embryos were sacrificed on day 5 after initial injections, and the number of human cells colonized the CAM was determined by AluqPCR (Fig. 4A). Analysis of tumor cell colonization showed that all three anti-CDCP1 antibodies substantially inhibited both HeLa-CDCP1 (fig. 4A, left panel) and PC-hi/diss (Fig. 4B, right panel) cells, with C20Fc demonstrating maximal and significant inhibition down to 15 – 45% of control scFv-Fc.

Evaluation of anti-CDCP1 scFv-Fc antibodies in an experimental tumor metastasis model in mice

Having demonstrated the efficiency of human anti-CDCP1 by reducing experimental metastasis in chick embryos, the effect on tumor cell colonization in the mouse model was studied. Since C20Fc exhibited maximal inhibitory activity against both carcinoma cell types in the chick embryo (Fig. 4A), this antibody was chosen for further evaluation of its function blocking activity in experimental metastasis in mice. Treatment with C20Fc caused a nearly complete inhibition (>85%) of metastatic burden in the lungs of mice injected with highly colonizing PC3-hi/diss (Fig. 4B, right panel) and approximately 60% inhibition of lung metastasis in mice injected with low colonizing HeLa-CDCP1 cells (Fig. 4B, left panel), thereby validating our initial inhibitory effects observed in the chick embryo model.

Anchorage independent growth of CDCP1-expressing cells is suppressed by anti-CDCP1 antibody C20Fc

The inhibitory effects of the C20Fc antibody on tumor cell survival and growth were evaluated in an anchorage independence assay where inhibition of colony formation is considered a stringent in vitro test of the anticancer activity of an anti-tumor drug candidate. Antibody C20Fc reduced significantly (by approximately 50%) colony formation of CDCP1 positive cells, both HeLa-CDCP1 and PC-hi/diss, but did not affect the growth of CDCP1 negative, HeLa-neo cells (Fig. 5).

CDCP1-C20Fc-Mediated Cell Cytotoxicity

To further evaluate targeting of CDCP1 by human anti-CDCP1 antibodies in the context of antibody-mediated therapy, we analyzed whether engagement of CDCP1 by C20Fc induced antibody-ligand complex internalization. To this end, a cell-killing assay was utilized in which cell death is mediated by internalization-dependent delivery of antibody-toxin conjugates. HeLa-CDCP1 and PC-hi/diss cells were incubated with pre-formed complexes of individual primary antibodies (human scFv-Fc fusion and or murine mAbs) and a corresponding species-specific saporinconjugated secondary antibody. Reduced cell viability indicates antibody internalization and successful saporin delivery. As shown in Fig. 6, the anti-transferrin receptor (TfR) antibody²³ induced significant cell death as expressed as remaining cell viability (10% remaining). Therefore, anti-TfR served as a positive control for antibody internalization since both HeLa and PC-3 parental cells express the transferrin receptor protein.^{24,25} As expected, no cell toxicity was observed with the primary control antibodies, normal mouse IgG or human A4Fc; nor was toxicity seen with toxinconjugated secondary antibodies in the absence of any primary antibody (Fig. 6). In contrast, treatment with mAb 41-2 and C20Fc resulted in a substantial increase of toxin-mediated cell death of HeLa-CDCP1 cells (40% and 50% respectively). The viability of PC-hi/diss cells was reduced to a lesser extent (80% by mAb 41-2 and 70% by C20Fc). Importantly, neither mAb 41-2 nor C20Fc affected viability of HeLa-neo cells, indicative of specific internalization of the anti-CDCP1-CDCP1 ligand complexes by CDCP1-expressing tumor cells.

Discussion

CDCP1 is a highly overexpressed gene that encodes a putative transmembrane protein, containing three CUB domains in the extracellular part in human colon cancer and lung cancer

that was discovered using representational difference analysis and cDNA chip technology in 2001.¹ Indeed, overexpression of CDCP1 has been reported to occur in human colorectal cancer, lung, and renal cell carcinoma and breast cancer.^{1,5,9,26} From a biochemical standpoint CDCP1 is a substrate of SRC kinase with Tyr734 becoming phosphorylated;^{2,17,18} while phosphorylated CDCP1 is associated within a complex with SRC kinase and PKC δ . Of note is that the tyrosinephosphorylated CDCP1 is required to overcome anoikis in lung cancer cells.⁴

A particularly intriguing paper by Awakura and his colleagues provided strong evidence that expression of CDCP1 in renal cell carcinoma inversely correlated with disease-specific and recurrence-free survivals by microarray, quantitative real-time PCR and immunohistochemical analysis for renal cell carcinoma specimens.⁹ Additionally, Ikeda and Oda also reported that high expression of CDCP1 correlates well with relapse rate, poor prognosis, and occurrence of lymph node metastasis.¹³

It has been suggested that CDCP1 plays an important role in tumor growth and survival, indeed the prognosis of patients with overexpressing CDCP1 tumors is much poorer than CDCP1 negative or low expressing tumors.¹⁶ Clinical cancer specimens and cell-based *in vitro* and *in vivo* observations strongly suggest that CDCP1 is an excellent target for the development of therapeutic antibodies in cancer therapy.¹⁶ In this regard, generation of fully human anti-CDCP1 antibodies with function blocking capabilities could represent new powerful tools for targeted cancer therapy. In our study, we panned a phage human antibody library against CDCP1 expressing cell lines and immunopurified CDCP1, with the intent of identifying human antibodies that prevent metastasis *in vivo*. Notably, we used naïve phage antibody libraries as unbiased affinity repertoire to select for CDCP1-targeting scFvs. Applying this tactic, a panel of targeting scFvs was identified, including three scFvs that were further characterized. By varying the selection target between cell-bound CDCP1 and immunopurified CDCP1, we should be able to select antibodies targeting different epitopes, thereby broadening therapeutic applicability. All identified scFvs bound specifically to CDCP1-expressing HeLa cells, and one of the identified antibodies was shown to inhibit tumor metastasis in chick embryos as well as in an *in vivo* mouse model. These highly desirable properties make human anti-CDCP1 antibodies attractive candidates for further therapeutic development.

One of the goals of this study was to test the efficacy of our antibodies *in vivo*, however, the rapid blood clearance of monovalent scFvs due to their small size can be a limiting factor for the use of these molecules in passive immunotherapy. Bivalent molecules containing the Fc region are more effective at stimulation of Fc-mediated effector functions and have an increased serum half-life *in vivo*.²⁷ To exploit these effector functions and to optimize the pharmacokinetic properties of our antibodies, selected scFvs were converted to scFv-Fc fusion proteins. The Fc expression vector used in these experiments, pSec-Fc, contains the hinge and the human IgG1 Fc region. Notably, antibody engineering of the Fc domain allows for the fine-tuning of effector functions and physiological half-life. Because of the efficacy observed of these human anti-CDCP1 scFv-Fc antibodies, future studies using engineered antibodies are warranted and will further accentuate the biological activities against metastatic malignant disease.

Previously, Siva and colleagues identified the murine anti-CDCP1 antibody 25A11 by whole cell panning and subtraction with red blood cells.⁸ This antibody inhibited tumor cell migration and invasion *in vitro*, and the targeted cell surface CDCP1 was internalized together with the 25A11 antibody. When 25A11 that was coupled to the cytotoxin saporin, either directly or via a secondary antibody, this toxin conjugate caused killing of CDCP1-positive prostate cancer PC-3 cells killing *in vitro*; not surprisingly, the anti-CDCP1 immunotoxin also inhibited primary tumor growth and metastasis of PC-3 cells in a mouse xenograft model. Interestingly,

25A11 without toxin failed to show any inhibitory effects for tumor metastasis.⁷ In sharp contrast, our human anti-CDCP1 antibody C20Fc inhibited *in vivo* tumor metastasis and *in vitro* colony formation without toxin conjugation. At this juncture the mechanistic difference between these two antibodies remains to be explored in future studies.

One promising area of anti-neoplastic drug development is the exploration of tumor susceptibility to targeted therapy.²⁸ Antibodies selectively targeting internalizing epitopes could be harnessed to achieve specific intracellular delivery of therapeutic agents.²⁹ Two of the identified scFvs were shown to be capable of targeted intracellular payload delivery into CDCP1-expressing cells.

In view of the fact that saporin alone shows low toxicity towards whole cells, we utilized the Hum-Zap assay to prove that indeed, C20Fc was capable of internalizing into HeLa-CDCP1 and PC-hi/diss cells. The number of viable cells decreased almost 70% for HeLa-CDCP1 cells and 30% for PC-hi/diss cells when treated with equal amounts of Hum-ZAP and C20Fc. While the anti-CDCP1 mAb 41-2, obtained previously from subtractive immunization, also displayed internalization into CDCP1-positive cells as well as inhibited *in vivo* tumor metastasis,² it is important to note that 41-2 is a fully murine immunoglobulin, which limits its clinical applicability.

Over the years there has been a steady increase in our understanding of CDCP1 and its involvement in cancer proliferation. Nevertheless, a number of critical aspects of CDCP1-mediated physiology remain unanswered. The most critical might be to identify the natural ligand(s) and to establish functional roles of CDCP1, which is needed to advance our understanding how CDCP1 interactions with other proteins and processing of CDCP1 impact cell signaling in cancer and normal physiology.

In this report, we demonstrate that the human anti-CDCP1 antibody C20Fc was effective in inhibiting colony formation, thereby underlining the important role of CDCP1 in cancer progression and metastasis and indicating its potential in drug development. Although these data provide an early proof-of-concept for inhibition of tumor metastasis, our findings demonstrate that fully human anti-CDCP1 antibodies can achieve the same feat in inhibiting tumor cell dissemination.

Acknowledgments

This work was supported by the Skaggs Institute for Chemical Biology (K.D.J.) and the National Institutes of Health (CA105412 to J.P.Q.).

ABBREVIATIONS USED

CDCP1	CUB Domain Containing Protein 1
scFv	single-chain variable fragment
mAb	monoclonal antibody
MSC	mesenchymal stem cell
NPC	neural progenitor cell
PKC δ	protein kinase C delta
DMEM	Dulbecco's Modified Eagle's Medium
IgG	immunoglobulin G
FITC	fluorescein isothiocyanate

CAM	chorioallantoic membrane
NOD-SCID	non-obese diabetic - severe combined immunodeficiency
LMA	low melting point agarose
CDR	complementarity determining region
scFv-Fc	C-terminal Fc-fused antibodies
SB	super broth
HRP	horseradish peroxidase
FBS	fetal bovine serum
PBS	phosphate buffered saline

References

1. Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. *Oncogene* 2001;20:4402–8. [PubMed: 11466621]
2. Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, Testa JE, Quigley JP. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. *Oncogene* 2003;22:1783–94. [PubMed: 12660814]
3. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. *Oncogene* 2005;24:5333–43. [PubMed: 16007225]
4. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. *Mol Cell Biol* 2007;27:7649–60. [PubMed: 17785447]
5. Perry SE, Robinson P, Melcher A, Quirke P, Buhning HJ, Cook GP, Blair GE. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. *FEBS Lett* 2007;581:1137–42. [PubMed: 17335815]
6. Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y, Yanagihara K, Sakai R. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. *Am J Pathol* 2008;172:1729–39. [PubMed: 18467693]
7. Siva AC, Wild MA, Kirkland RE, Nolan MJ, Lin B, Maruyama T, Yantiri-Wernimont F, Frederickson S, Bowdish KS, Xin H. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. *Cancer Res* 2008;68:3759–66. [PubMed: 18483259]
8. Siva AC, Kirkland RE, Lin B, Maruyama T, McWhirter J, Yantiri-Wernimont F, Bowdish KS, Xin H. Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells. *J Immunol Methods* 2008;330:109–19. [PubMed: 18096183]
9. Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T, Myoumoto A, Akiyama H, Ito N, Kamoto T, Manabe T, Nobumasa H, Tsujimoto G, Ogawa O. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. *J Cancer Res Clin Oncol* 2008;134:1363–9. [PubMed: 18483744]
10. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. *Am J Pathol* 2009;174:1756–65. [PubMed: 19349359]
11. Deryugina EI, Conn EM, Wortmann A, Partridge JJ, Kupriyanova TA, Ardi VC, Hooper JD, Quigley JP. Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. *Mol Cancer Res* 2009;7:1197–211. [PubMed: 19671673]
12. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. *Clin Cancer Res* 2009;15:2311–22. [PubMed: 19318475]

13. Ikeda JI, Oda T, Inoue M, Uekita T, Sakai R, Okumura M, Aozasa K, Morii E. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. *Cancer Sci* 2008;100:429–33. [PubMed: 19077003]
14. Conze T, Lammers R, Kuci S, Scherl-Mostageer M, Schweifer N, Kanz L, Buhring HJ. CDCP1 is a novel marker for hematopoietic stem cells. *Ann N Y Acad Sci* 2003;996:222–6. [PubMed: 12799299]
15. Buhring HJ, Kuci S, Conze T, Rathke G, Bartolovic K, Grunebach F, Scherl-Mostageer M, Brummendorf TH, Schweifer N, Lammers R. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. *Stem Cells* 2004;22:334–43. [PubMed: 15153610]
16. Wortmann A, He Y, Deryugina EI, Quigley JP, Hooper JD. The cell surface glycoprotein CDCP1 in cancer-Insights, opportunities, and challenges. *IUBMB Life* 2009;61:723–730. [PubMed: 19514048]
17. Brown TA, Yang TM, Zaitsevskaya T, Xia Y, Dunn CA, Sigle RO, Knudsen B, Carter WG. Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia. *J Biol Chem* 2004;279:14772–83. [PubMed: 14739293]
18. Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCdelta is a phosphotyrosine binding domain. *Cell* 2005;121:271–80. [PubMed: 15851033]
19. Conn EM, Botkjaer KA, Kupriyanova TA, Andreasen PA, Deryugina EI, Quigley JP. Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion. *Am J Pathol* 2009;175:1638–52. [PubMed: 19729488]
20. Mao S, Gao C, Lo CH, Wirsching P, Wong CH, Janda KD. Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. *Proc Natl Acad Sci U S A* 1999;96:6953–8. [PubMed: 10359820]
21. Gao C, Mao S, Ditzel HJ, Farnes L, Wirsching P, Lerner RA, Janda KD. A cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library. *Bioorg Med Chem* 2002;10:4057–65. [PubMed: 12413859]
22. Gao C, Brümmer O, Mao S, Janda KD. Selection of Human Metalloantibodies from a Combinatorial Phage Single-Chain Antibody Library. *J. Am. Chem. Soc* 1999;121:6517–6518.
23. Rao KK, Shapiro D, Mattia E, Bridges K, Klausner R. Effects of alterations in cellular iron on biosynthesis of the transferrin receptor in K562 cells. *Mol Cell Biol* 1985;5:595–600. [PubMed: 2985960]
24. Keer HN, Kozlowski JM, Tsai YC, Lee C, McEwan RN, Grayhack JT. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. *J Urol* 1990;143:381–5. [PubMed: 1688956]
25. Bleil JD, Bretscher MS. Transferrin receptor and its recycling in HeLa cells. *EMBO J* 1982;1:351–5. [PubMed: 6325161]
26. Ikeda JI, Morii E, Kimura H, Tomita Y, Takakuwa T, Hasegawa JI, Kim YK, Miyoshi Y, Noguchi S, Nishida T, Aozasa K. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. *J Pathol* 2006;210:75–84. [PubMed: 16823897]
27. Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD. Expression of single-chain Fv-Fc fusions in *Pichia pastoris*. *J Immunol Methods* 2001;251:123–35. [PubMed: 11292488]
28. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. *Int J Cancer* 2004;109:759–67. [PubMed: 14999786]
29. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. *Nat Rev Drug Discov* 2006;5:147–59. [PubMed: 16424916]

Figure 1.

Selected scFv antibodies on phage by whole cell ELISA. Positive scFv antibody expressing phage clones were selected by whole cell ELISA with CDCP1 expressing HeLa cells (HeLa-CDCP1) and Neo expressing HeLa cells (HeLa-neo). Data are the mean of triplicate wells. Error bars indicate the SD.

```

                                CDR-H1                                CDR-H2
C14  QVQLVQSGAEVKKPGSSVKLSQAASGTFSTYVISHVRQAPGQGLEWMGGIIEIFFTFDY
C25  QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVROATGQGLEWMGWNINNSGNTGY
C20  QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVROATGQGLEWMGWINPNGGGTNY

                                CDR-H3
C14  ARKFQGRVTITADESTSTAYMELRGLKPEDTAVYYCAGPYNSRPGLGGNYYYVMDVWGQG
C25  AOKFQGRVTMTTRNTSISTAYMELSSLRSEDTAVYYCASN-----IAAAGTHWYFDLWGRG
C20  AOKFQGRVTMTTRDTSISTAYMEFSRLRADDTAVYYCASG-----VGAAN--ALDIWQGG

                                Linker                                CDR-L1
C14  TLVTVSSGGGGSGGGSGGGSGGGSNFMLTQ-FHSMSESPGKTVTTPCTRESGSIASN---YV
C25  TLVTVSSGGGGSGGGSGGGSGGGSNFMLTQ-FPSVSESPGKTVTTSCTRESGSIASN---YV
C20  TMVTVSSGGGGSGGGSGGGSGGGSETTLTQSFLSLSVTPGEPASISCKSSQSLHNSGNYNL

                                CDR-L2
C14  QWYQORFGSSPTTVIYDDNQRPSPGVPDRFSGSIDSSNSASLTISGLKTEADAYFCQSY
C25  QWYQORFGSSPTTVIYDDNQRPSPGVPDRFSGSLDTSSNSASLTISGLKTEADAYFCQSY
C20  DWYLQKPGQSPQLLYLGSDRASGVDPDRFSGS--CGSDFTLRISRVEAEDVGIYYCMAA

                                CDR-L3                                Human Fc Hinge
C14  DSSSVIFGGGTHLTVLGLGGLCPPCPAPELLGGPSVFLFPP
C25  DDDSVIFGGGTHLTVLGLGGLCPPCPAPELLGGPSVFLFPP
C20  LRTFPTFGGGTKVEIKRGLGGLCPPCPAPELLGGPSVFLFPP

```

Figure 2.

Alignment of anti-CDCP1 antibodies. Multiple sequence alignment was performed with AlignX (Invitrogen). Identical residues of three antibodies are shown in red, of two antibodies are shown in blue. Different residues are shown in black and weakly similar in green. CDR regions of antibodies, linker and the Fc hinge are indicated above the sequences.

Figure 3.

Binding of scFv-Fc antibodies to CDCP1 positive cells. scFv-Fc antibodies recognize cancer cells based on their expression of CDCP1. Several independent experiments on each of these cell types gave similar results. Shown are flow cytometric analyses with binding of scFv-Fc antibodies to cells detected as fluorescence signal of fluorescein labeled anti-human IgG Fc goat 2nd antibody. 41-2 mouse monoclonal antibody was used as a positive control of anti-CDCP1 binding with using a fluorescein labeled anti-mouse IgG goat 2nd antibody.

Figure 4.

Experimental metastasis of CDCP1 positive cells in chick embryos (A) and mice (B) is sensitive to anti-CDCP1 C20Fc. (A) HeLa-CDCP1 cells (left panel) or PC-hi/diss (right panel) were injected i.v. into chick embryos (5×10^4 cells per embryo) along with 25 μ g of control A4Fc or anti-CDCP1 scFv-Fc C14Fc, C20Fc and C25Fc. On day 5 following inoculations, the levels of CAM colonization were determined by Alu-qPCR. *, $P < 0.05$ in unpaired t -test with Welch's correction; **, $P < 0.05$ in two-tailed unpaired t -test. (B) HeLa-CDCP1 cells (left panel, 1×10^6 cells/mouse) or PC-hi/diss (right panel, 5×10^5 cells/mouse) were injected i.v. into immunodeficient NOD-SCID mice (4–6 mice per group) along with 100 μ g of control A4Fc or anti-CDCP1 C20Fc. Additional injections of corresponding antibodies were performed i.p.

on days 1 and 2 after cell injections. Levels of lung colonization by tumor cells were determined 4 weeks (HeLa-CDCP1 cells) and 8 weeks (PC-hi/diss cells) after cell inoculations. Data are means $\pm$ SEM of numbers of human cells per 10^6 host cells determined by qPCR. ***, $P < 0.05$ in a two-tailed unpaired *t*-test.

Figure 5.

Antibody effect for anchorage independent colony formation of cancer cells in soft agar. Colony formation of CDCP1 expressing cell lines, PC-3LC and HeLa-CDCP1 or CDCP1 negative cell line, HeLa-Neo, was studied in 0.3 % LMA containing complete media for 2 weeks. The number of colonies was counted in eight random fields from each plate using a microscope. Data shown are the mean $\pm$ S.D for the number of colonies in each field. Significant difference is indicated by asterisks (*) when P value was less than 0.05 (*t*-test).

Figure 6.

CDCP1 antibody-mediated internalization and tumor cell killing. Internalization was studied using anti-CDCP1 antibodies with an appropriate saporin secondary conjugate for indirect immunotoxin experiments. A PBS vehicle control without antibody served as blank. Pre-incubated 40 ng primary antibodies and 40 ng/well of goat anti-mouse saporin (mAb-ZAP) or anti-human secondary saporin (Hum-ZAP) conjugates were added to each well. Percent cell viability compared to nontreated control was determined for primary antibodies with appropriate secondary saporin conjugate. Experiments were done in triplicate over three plates, and a representative graph for the study is shown.